Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis

Anzel Saeed; Kuldeep Dalpat Rai; Muzammil Saeed

doi:10.1016/j.livres.2024.07.002

Liver Research ›› 2024, Vol. 8 ›› Issue (3) :193 -194. DOI: 10.1016/j.livres.2024.07.002

Correspondence

research-article

Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis

Author information +

History +

PDF (180KB)

Cite this article

Download citation ▾

Anzel Saeed, Kuldeep Dalpat Rai, Muzammil Saeed. Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis. Liver Research, 2024, 8(3): 193-194 DOI:10.1016/j.livres.2024.07.002

登录浏览全文

4963

注册一个新账户忘记密码

Authors’ contributions

Anzel Saeed: Writing e review & editing, Conceptualization. Kuldeep Dalpat Rai: Writing e original draft. Muzammil Saeed: Writing e original draft.

Declaration of competing interest

The authors declare that there is no conflicts of interest.

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohe-patitis. N Engl J Med. 2017;377:2063-2072. https://doi.org/10.1056/NEJMra1503519.

[2]	Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver ﬁbrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389e 397 (e10). https://doi.org/10.1053/j.gastro.2015.04.043.

[3]	Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by ﬁbrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatol-ogy. 2017;65:1557-1565. https://doi.org/10.1002/hep.29085.

[4]	Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. J Hepatol. 2018;68:362-375. https://doi.org/10.1016/j.jhep.2017.10. 015.

[5]	Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20. https://doi.org/10.1038/nrgastro.2017.109.

[6]

U.S. Food and Drug Administration. FDA approves ﬁrst treatment for patients with liver scarring due to fatty liver disease. Published March 14, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-ﬁrst-treatment-patients-liver-scarring-due-fatty-liver-disease. Accessed 19 May 2024.

[7]

Dutta D, Kamrul-Hasan ABM, Mondal E, Nagendra L, Joshi A, Bhattacharya S. Role of resmetirom, a liver-directed, thyroid hormone receptor beta-selective agonist, in managing nonalcoholic steatohepatitis: a systematic review and meta-analysis. Endocr Pract. Published online May 1, 2024. doi:10.1016/j.eprac.2024.04.016.

[8]	Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver ﬁbrosis. N Engl J Med. 2024;390:497-509. https://doi.org/10.1056/NEJMoa2309000.

[9]	Zhao J, Li B, Zhang K, Zhu Z. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis of ran-domized controlled trials. Medicine (Baltimore). 2024;103:e37271. https://doi.org/10.1097/MD.0000000000037271.